Physician profile
Elyse J Rubenstein
NPI 1508895095
$15,345.90
in general payments reported to CMS, 2019-2025
33 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,184 · 2020: $1,825 · 2021: $1,634 · 2022: $2,426 · 2023: $2,058 · 2024: $2,390 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,235 · Education: $42.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,235.34 |
| Education | $42.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,926.95 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,771.34 | 2019-2025 | Evenity, Prolia, Enbrel |
| Janssen Biotech, INC. | $1,452.53 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Glaxosmithkline, LLC. | $1,354.46 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $1,002.07 | 2019-2025 | |
| Pfizer INC. | $774.04 | 2019-2025 | |
| Horizon Therapeutics Plc | $595.75 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $594.52 | 2019-2024 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $555.97 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.83 | 2019-2025 | Ofev, Cyltezo |
| Janssen Scientific Affairs, LLC | $360.81 | 2019-2020 | |
| Ucb, INC. | $317.28 | 2024-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $284.43 | 2019-2025 | Saphnelo |
| Mallinckrodt Enterprises LLC | $273.19 | 2019 | |
| Radius Health, INC. | $229.60 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $226.38 | 2023-2025 | Teriparatide |
| Genzyme Corporation | $180.73 | 2019-2025 | |
| Celgene Corporation | $154.82 | 2019 | |
| Fresenius Kabi USA, LLC | $146.94 | 2023-2025 | Idacio |
| Genentech USA, INC. | $130.60 | 2019-2025 | Actemra |
| Tersera Therapeutics LLC | $83.90 | 2019 | |
| Alexion Pharmaceuticals, INC. | $82.07 | 2019-2021 | |
| Depuy Synthes Sales INC. | $65.87 | 2022 | |
| Ani Pharmaceuticals, INC. | $58.36 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Globus Medical, INC. | $51.72 | 2024 | Xlif |
| Avanos Medical | $44.96 | 2024 | Genvisc 850 Sodium Hyaluronate |
| Celltrion USA INC. | $42.19 | 2023 | Yuflyma |
| Vertiflex, INC. | $33.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.57 | 2019 | |
| Sobi, INC | $26.39 | 2022 | |
| Fidia Pharma USA INC. | $22.30 | 2021 | |
| Ibsa Pharma INC. | $21.12 | 2024 | Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $15.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.